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blation for Atrial
ibrillation: Are Cures Really Achieved?
ntonio Pacifico, MD, Philip D. Henry, MD
ouston, Texas
During the past 10 years numerous studies on the treatment of paroxysmal atrial fibrillation
(AF) by right and left atrial ablation procedures have been published. The results of studies
based on follow-up periods of a few months have been repeatedly interpreted as providing
evidence for curative therapy. However, insufficient focus on the variability of the natural
history of paroxysmal AF, the inadequate detection of silent arrhythmic events, the eclectic
post-interventional use of antiarrhythmic drugs, and the lack of appropriate control groups
make the reports unconvincing. Randomized controlled trials are needed to confirm
postulated long-term cure rates for AF. (J Am Coll Cardiol 2004;43:1940–2) © 2004 by
the American College of Cardiology Foundationw
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phe limited success of drug therapy for the prevention and
reatment of atrial fibrillation (AF) has incited clinical
nvestigators to explore alternative treatments (1–3). Vari-
us preventive electrophysiologic strategies ranging from
ultisite atrial pacing to rate smoothing, antitachycardia
acing, and atrial defibrillators have been proposed, but
hese therapies remain largely investigational (4). A com-
on therapy for “drug-refractory” AF is ventricular pacing
fter atrioventricular nodal ablation, a palliative treatment
till requiring anticoagulation (5). But perhaps the most
ntriguing nonpharmacologic therapy is that seeking to cure
F by the targeted destruction of atrial muscle. Working in
he footsteps of arrhythmia surgeons, electrophysiologists
ave devised during the past decade catheter-based ablation
rocedures inspired by the Corridor and Maze operations.
n their most recent work on “pulmonary vein isolation,”
hey interpreted their interventions to cure AF in more than
5% of the patients (6–9). These cure rates published in
eer-reviewed journals have put considerable pressure on
racticing electrophysiologists to make ablation for AF
vailable to their patients. Consequently, the procedure has
een adopted widely, but registries documenting the efficacy
nd safety of atrial ablation as applied in the community are
ot available. Some operators have failed to achieve high
ure rates (10). One investigator wondered whether looking
or curative atrial scars was “hype or hope” (11), and another
elt that ablation for AF was “not a reality” (12).
Although surgeons and interventionalists like to debate
hether clinical research based on randomized controlled
rials should or could be implemented in their fields, there is
eally no doubt that new treatments require comparison
ith established treatments or no treatment (placebo or
ham operations) (13). Momentarily forgetting the trialists’
pecial criteria-guided assembly of cohorts, randomization
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ower estimates, and survival statistic applying the
ntention-to-treat principle, the simplest and most modest
valuation of therapeutic efficacy is to compare patients
eceiving a new experimental treatment with those who
ave previously received either no therapy or another ther-
py. Describing patients who received no therapy in the past
re historical controls that help us define the natural history
f a disease. In a recent meta-analysis summarizing 91
andomized trials of the drug treatment of AF (total number
f patients 8,563), the maintenance of sinus rhythm over
ollow-up periods lasting1 to 1,096 days (mean SD, 46
136) ranged in the placebo group between 0% and 90%
mean, 32%) and in the drug group between 0% and 100%
mean, 52%; p  0.0001 vs. placebo) (1). The extensive
eta-analysis suggests two points: 1) overall treatment
fficacy with drug versus placebo is highly significant al-
hough modest in magnitude; and 2) the relapse rate over
elatively short periods both with and without antiarrhyth-
ic drug treatment is spectacularly variable, ranging essen-
ially between 0 and 100%. In their review of paroxysmal AF
PAF), Lip and Li Saw Hee (3) emphasized the difficulty in
elineating a natural history of this disease. One of the
ajor problems in the assessment of PAF is that its episodes
re very frequently silent (14,15). In patients receiving
mplantable devices with long-term Holter memory func-
ion, more than 50% of the patients exhibit unsuspected
AF (14,15). A seeming cure of PAF may simply represent
he conversion of early symptomatic to subsequent asymp-
omatic disease (14). Therapeutic efficacy of atrial ablation
ritically depends upon the use of special tools for the
etection of asymptomatic arrhythmias (15,16). Patients
eek medical help selectively during periods of symptomatic
xacerbations, not periods of symptomatic remission. There
s evidence that the initial episodes of AF are most likely to
roduce anxiety and be poorly tolerated, whereas increasing
hronicity of AF may favor asymptomatic episodes, espe-
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June 2, 2004:1940–2 Ablation for AFially in the elderly population (14). Post-interventional
ymptom modification in patients willing to submit them-
elves repeatedly to hazardous invasive procedures such as
F ablation may importantly depend upon a placebo effect
13), a phenomenon strikingly illustrated in recent sham- or
lacebo-controlled trials of myocardial revascularization
17,18). Post-interventional appraisal of PAF is most diffi-
ult and requires special methodological precautions that
ave been extensively evaluated for other chronic relapsing-
emitting diseases with erratic clinical course, multiple
clerosis in particular (19).
Claiming cure or palliation in the absence of random-
zed controlled trials ignores modern evidence-based
edicine. Concurrent nonrandomized control groups do
ot eliminate selection bias and inequalities between
roups. Prospective epidemiologic studies and observa-
ional registries have demonstrated that AF in industri-
lized societies is a highly age-dependent disease. Groups
ounger than 60 years of age may amount to no more
han 10% of the total AF population (5,20,21). There-
ore, reports on AF ablation involving patients younger
han a mean age of 60 years (for example, 7,22,23) or
ndeed 50 years (6) are examples of patient selection.
urthermore, if patients are also stated to exhibit no signs
f structural heart disease (7,22), they may be viewed as
uffering from “lone AF,” a controversial type of AF that
ay be associated with low long-term relapse rates (24).
nother major drawback of assessing therapeutic efficacy
ithout appropriate controls is the failure to consider
oncomitant therapy. In most AF ablation studies, au-
hors used eclectically antiarrhythmic agents on top of
blation therapy without prospective specification of drug
ndication, type, or dosage. Knowing that drug therapy
or AF is partly effective over short periods (1) makes the
valuation of superimposed ablation therapy virtually
mpossible. A minimal requirement would be to obtain
uantitative Holter type assessments of AF burden seri-
lly before and after invasive intervention while keeping
harmacologic treatment invariant.
The literature on ablation for AF suffers in part from the
ame shortcomings as that on arrhythmia surgery for AF. In
oth cases, uncontrolled studies often describe single-center
xperiences with repeatedly modified procedures and newly
ested instrumentation that make the evaluation of sequential
tudies from single institutions or comparisons between
nstitutions impossible. Over recent years, single groups
rematurely claimed success, for instance, success with right
trial ablation or ostial pulmonary vein ablation (22,23,25),
procedure that invites pulmonary vein stenosis (26). In two
tudies reported by one group, the mean age of consecutive
trial ablation patients collected “from all over Italy” (8)
uring completely overlapping study periods differed between
typical 65 years in one study (8) and an atypical young age
50 years) in the other (7). This epidemiologically unlikely
vent suggests eclectic grouping rather than the reporting of
onsecutive patients. The second of these two studies (8) was aalled “controlled,” although the indication for ablation was
etermined by either the patient’s preference or the electro-
hysiologist’s judgment, arguably not exemplary control.
his study reported a remarkable reduction in sudden
ardiac death (SCD) rate (and total cardiovascular mortal-
ty) by atrial ablation. During a mean observation of
pproximately 2.4 years, there were no SCDs among 589
blated patients, but 12 among 582 non-ablated controls
no statistical analysis provided) (8). The apparent protec-
ion against SCD occurred in patients exhibiting an elevated
eft ventricular mass (138 g/m2) estimated by an unknown
chocardiographic method. In a recent Italian multicenter
tudy (MAssa Ventricolare sinistra nell’Ipertensione arte-
iosa [MAVI]), this degree of left ventricular hypertrophy
as associated with a high SCD risk (27). Intimating that
uch studies provide controlled data demonstrating the
eduction of mortality and morbidity by atrial ablation
annot be accepted without reservations. Another pervasive
roblem in recent atrial ablation reports is a variable or
bsent definition of the term cure of AF. As with earlier
eports on Maze operations, there is after approximately 10
ears of clinical experimentation with continually modified
rocedures a lack of randomized studies providing convinc-
ng survival-statistical information on therapeutic gains,
isks, and complications. Important possible complications,
uch as high radiation doses from single or repeated proce-
ures or postprocedural cognitive deficits from silent em-
olic brain injury (28,29), have been largely ignored.
We recognize that ablation for AF, if successful, would
epresent an important advance in cardiovascular therapeu-
ics and we truly applaud research in this field. However, it
s the responsibility of peer-reviewed cardiology journals to
rovide a critical and balanced assessment of the work
erformed in this field. Editors and reviewers should make
n effort to resolve uncertainties arising from contradictory
eports. Recently, one group of authors (30) concluded in
he abstract of their report that “isolation of pulmonary
eins is not crucial for curing AF.” Four months later, in the
ame journal, another group (31) concluded in their abstract
hat “total electrical isolation of the pulmonary venous
egion. . .appeared necessary for success.” The second paper
31) did not relate to the preceding one (30). Methodolog-
cal research and feasibility appraisals should be described as
uch without claims to achieve cure rates as evaluated in
hase III clinical trials. Also, claims of cure should be based
n adequate follow-ups of at least two years. Knowing the
pidemiology of AF, in particular its association with
dvanced age and cardiovascular risk factors (5,20,21), and
onsidering the diffuse structural alterations affecting the
tria (atrial and pulmonary vein enlargement, apoptosis of
ardiomyocytes, deposition of matrix proteins, and extensive
enetic reprogramming) (32), the postulate that the place-
ent of a few scars can truly cure venoatrial disease remains
rovocative. Previous experience with ablation therapy for
entricular tachyarrhythmias has documented the difficulties
rising from diffuse myocardial disease (33). Nonvalvular
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Ablation for AF June 2, 2004:1940–2F is a tenacious erratic disease evolving over a lifetime, and
rief post-interventional follow-ups over periods of months
hould be interpreted cautiously.
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